BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Vivace Therapeutics\, Inc readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Vivace Therapeutics\, Inc's drugs
  run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07824986-2803@assetmemo.bio
DTSTAMP:20261121T005946Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:VT3989: Phase 3 readout est. (NCT07824986)
DESCRIPTION:VT3989\, phase 3.\nStudy: A Phase 3 Trial in Advanced Epithelio
 id Mesothelioma\nEstimated primary completion: 1 May 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/vt3989#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07824986
URL:https://assetmemo.bio/drug/vt3989#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04665206-2803@assetmemo.bio
DTSTAMP:20261121T005946Z
DTSTART;VALUE=DATE:20291102
DTEND;VALUE=DATE:20291103
SUMMARY:VT3989: Phase 1/2 readout est. (NCT04665206)
DESCRIPTION:VT3989\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Study 
 to Evaluate VT3989 in Patients With Metastatic Solid Tumors\nEstimated pri
 mary completion: 2 November 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/vt3989#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT04665206
URL:https://assetmemo.bio/drug/vt3989#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
